Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
170 hedge funds and large institutions have $592M invested in Meridian Bioscience Inc in 2017 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 58 increasing their positions, 46 reducing their positions, and 20 closing their positions.
61% more call options, than puts
Call options by funds: $667K | Put options by funds: $414K
35% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 20
26% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 46
15% more capital invested
Capital invested by funds: $514M → $592M (+$78M)
3% more funds holding
Funds holding: 165 → 170 (+5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$6.87M |
| 2 |
Millennium Management
New York
|
+$4.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.82M |
| 4 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
+$4.22M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIA
Dean Investment Associates
Beavercreek,
Ohio
|
-$5.71M |
| 2 |
PP
Prudential plc
London, England,
United Kingdom
|
-$3.62M |
| 3 |
BTW
Boston Trust Walden
Boston,
Massachusetts
|
-$3.26M |
| 4 |
JP Morgan Chase
New York
|
-$3.23M |
| 5 |
DCM
Dean Capital Management
Overland Park,
Kansas
|
-$3.01M |
VIVO Hedge Fund Activity: Q2 2017 in Review
170 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q2 2017, worth a combined $592M — up 15% from $514M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new VIVO positions and 20 closed out — a net gain of 7 holders — while 58 added to existing stakes and 46 trimmed.
The largest buyer was UBS Group, adding an estimated $6.87M. The largest seller was Dean Investment Associates, exiting entirely with an estimated $5.71M sold.
- 170 institutional investors held Meridian Bioscience Inc (VIVO) as of Q2 2017, up from 165 in Q1 2017.
- Funds reported $592M of Meridian Bioscience Inc stock for Q2 2017, up 15% quarter-over-quarter.
- 27 funds opened new Meridian Bioscience Inc positions in Q2 2017 and 20 closed out, a net change of +7 holders.
- The largest Meridian Bioscience Inc buyer in Q2 2017 was UBS Group, an estimated $6.87M added.
- The largest Meridian Bioscience Inc seller in Q2 2017 was Dean Investment Associates, an estimated $5.71M sold.
Based on aggregated 13F filings for Q2 2017.